The company was selected for the Viability Assessment Phase and advance to the next phase of the Challenge, the Deep Dive Assessment Phase
Boca Raton, FL: Through its product HEMOTAG, a device & cloud AI digital health platform for cardiac diagnostics and remote monitoring, Aventusoft LLC announced that it was selected to receive a $20,000 cash prize award for the Viability Assessment Phase and advance to the next phase of the Challenge, the Deep Dive Assessment Phase of the National Institutes of Health’s RADx Tech for Maternal Health Challenge.
Aventusoft’s HEMOTAG® technology is the first available technology providing innovative, non- invasive, rechargeable, reusable and secure cloud connected device & cloud AI digital health platform for cardiac diagnostics and remote monitoring. The solution provides non-invasive assessment alternative to invasive catheterization, allowing easy home-based & point-of-care diagnostic and monitoring technology. HEMOTAG provided assessment of left ventricular systolic function, left ventricular diastolic function, left ventricular pressure, congestion and lead-1 ECG based vital-sign assessment; can provide for assessing cardiomyopathy after delivery and monitoring patients postpartum. It uses everyday smartphones making it even more accessible and readily available without adding high costs. The device does not require skilled operators or specially trained physicians, enabling patient to self-test easily. The technology is specially designed to require very minimal data upload, enabling extension of care to postpartum individuals residing in maternity care deserts who may also have limited access to broadband internet or cellular signals. In recent years, mobile phones have become increasingly advanced and ubiquitous. The technology provided through this project is a tremendous opportunity to provide low-cost diagnostics to under-served populations. The benefit of this pioneering work is the development of an easy-to-use solution that can measure ventricular compliance, and thus enable improved care from home and during doctor visits, at community medical screenings, classes, and health fairs leading to healthier communities. For use at-home or at the point-of-care, this technology can be easily deployable across healthcare settings in hospitals, OB/GYN clinics, and community-based clinics, primary care physician, pediatrician offices, emergency medical services.
About Hemotag
HEMOTAG brings high-value hemodynamic assessment of cardiac pressure and function for use at-home and easily deployable across healthcare settings. The easy-to-use, wireless design allows accurate measurement of heart muscle performance. Sensor data is automatically sent to a HIPAA-compliant cloud and analyzed with machine-learning algorithms. Electronic patient reports are generated and made available to the care team within minutes.
About RADx
The Rapid Acceleration of Diagnostics Technology (RADx® Tech) for Maternal Health Challenge will award up to $8 million in prizes to accelerate the development of home-based and point-of-care (POC) maternal health diagnostic devices, wearables, or other remote sensing technologies. Successful technologies will enable extension of care (e.g., empower individuals with actionable health information they can use to inform their decisions about when to seek additional care) and ultimately reduce severe maternal morbidity and maternal mortality (SMM/MM) for individuals residing in maternity care deserts during the first year of the postpartum period (from day of delivery or end of pregnancy).